ReviewDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society2026
Competing Mortality Redefines the Net Benefit of Additional Surgery After Endoscopic Resection for T1 Colorectal Cancer in Older Adults.
Review in Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oncologic benefit of additional surgery after endoscopic resection (ER) for the treatment of T1 colorectal cancer (CRC) remains uncertain in older adults, because competing causes of mortality may attenuate the gain in survival. The proportion of patients aged ≥ 80 years has increased steadily, reflecting population aging. For patients with high-risk T1 CRC, the aim of additional bowel resection is to remove occult lymph node metastasis and reduce the risk of recurrence, and long-term studies have shown improvements in T1 CRC-related outcomes. However, age modifies the magnitude of this benefit. Cohort studies of high-risk T1 CRC have shown only small differences in 5-year cancer-specific survival between patients who underwent additional surgery and those who did not. Moreover, most deaths in the nonsurgical group were attributable to causes other than cancer. Data from meta-analyses have further suggested that the survival advantage associated with surgery becomes evident only after 10 years, indicating a substantial delay in its benefits. In contrast, the incidences of perioperative morbidity and short-term mortality increase with age and have immediate effects on prognosis. These findings indicate that the net survival benefit of additional surgery in older patients depends on the balance between the delayed oncologic benefit and the immediate treatment-related risks. Thus, although surgery remains appropriate for selected fit individuals, clinicians should consider the pathologic risk, frailty, comorbidity burden, and competing mortality of individual older patients with pT1 CRC in their decision-making to optimize outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.